重组凝血因子 VIII 治疗后的过敏反应：调查与治疗挑战
Anaphylaxis after treatment with recombinant factor VIII: investigation and therapeutic challenge.
作者信息
Pires Sofia, Sevivas Teresa, Loureiro Carla Chaves, Bartholomé Borja
机构信息
Pediatric Department, Hospital Pediátrico de Coimbra, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Haematology Department, Hospital Pediátrico de Coimbra, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
出版信息
BMJ Case Rep. 2018 Dec 14;11(1):e227426. doi: 10.1136/bcr-2018-227426.
We report a 10-year-old patient with haemophilia A developing anaphylaxis to recombinant factor VIII (octocog alfa). Allergic reactions, and especially anaphylactic events, are rare in patients with haemophilia A. The nature of these reactions is not fully understood. Here, we demonstrate a type I hypersensitivity reaction using sodium dodecyl sulfate-polyacrylamide gel electrophoresis immunoblotting assay. This test revealed itself as an essential diagnostic tool, as it allowed us to choose an alternative treatment (moroctocog alfa). Its safety was later confirmed by an uneventful challenge test.
我们报告了一名10岁的甲型血友病患者，对重组凝血因子VIII（奥曲凝血素α）发生过敏反应。甲型血友病患者发生过敏反应，尤其是过敏事件很少见。这些反应的本质尚未完全了解。在此，我们使用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳免疫印迹试验证实了I型超敏反应。该检测显示为一种重要的诊断工具，因为它使我们能够选择替代治疗药物（莫罗凝血素α）。其安全性随后通过顺利的激发试验得到证实。
Zotero 插件